InvestorsHub Logo
Followers 2
Posts 120
Boards Moderated 0
Alias Born 02/25/2012

Re: inversor86 post# 394

Thursday, 08/07/2014 7:05:26 PM

Thursday, August 07, 2014 7:05:26 PM

Post# of 232503
It's all about the shortest path to market

we all know pro 140 could well serve more than 200k in the US alone but for substitution therapy, <200k is their particular market

breakdown:

US

1.1 million HIV prevalence
902k diagnosed
604k undergoing treatment
390k undergoing treatment ccr5 only

it's a fraction of this 390k number (those with horrible side effects, resistance issues, etc) that would seek/require treatment substitution thus meeting orphan drug requirement of <200k

once on the market, doctors can prescribe for anyone
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News